Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of Once Daily Oral ZPL-3893787- 18 (30 mg) Administered for 12 Weeks in Adult Subjects With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2021
Price :
$35
*
At a glance
- Drugs Adriforant (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Sponsors Ziarco
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 24 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.
- 24 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2016.